Targeted therapy for BRAF V600E malignant astrocytoma

Clinical Cancer Research

Volumn 17, Issue 24, 2011, Pages 7595-7604

  Nicolaides, Theodore P ^a   Li, Huifang ^b   Solomon, David A ^b   Hariono, Sujatmi ^a   Hashizume, Rintaro ^a   Barkovich, Krister ^a   Baker, Suzanne J ^c   Paugh, Barbara S ^c   Jones, Chris ^d   Forshew, Tim ^e   Hindley, Guy F ^e   Graeme Hodgson, J ^f   Kim, Jung Sik ^b   Rowitch, David H ^a   Weiss, William A ^a   Waldman, Todd A ^b   David James, C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^e QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^f PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; PLX 4720; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; BRAF PROTEIN, HUMAN; INDOLE DERIVATIVE; N [3 (5 CHLORO 1H PYRROLO[2,3 B]PYRIDINE 3 CARBONYL) 2,4 DIFLUOROPHENYL]PROPANESULFONAMIDE; SULFONAMIDE;

ADOLESCENT; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CENTRAL NERVOUS SYSTEM TUMOR; CHILD; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENE SILENCING; GENETIC TRANSFECTION; GLIOMA CELL; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALIGNANT ASTROCYTOMA; MOLECULARLY TARGETED THERAPY; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHOOL CHILD; TREATMENT DURATION; TUMOR XENOGRAFT; WILD TYPE; AMINO ACID SUBSTITUTION; ANIMAL; ASTROCYTOMA; BRAIN TUMOR; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; GENETICS; INFANT; KAPLAN MEIER METHOD; METABOLISM; MUTATION; NUCLEOTIDE SEQUENCE; NUDE MOUSE; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE; TUMOR VOLUME; WESTERN BLOTTING;

ADOLESCENT; AMINO ACID SUBSTITUTION; ANIMALS; ASTROCYTOMA; BASE SEQUENCE; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CHILD; CHILD, PRESCHOOL; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; INDOLES; INFANT; KAPLAN-MEIER ESTIMATE; MICE; MICE, NUDE; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; RNA INTERFERENCE; SULFONAMIDES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS; YOUNG ADULT;

EID: 84055212088     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-1456     Document Type: Article

References (46)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352: 987-96. (Pubitemid 40349501)
2. Cohen KJ, Heideman RL, Zhou T, Holmes EJ, Lavey RS, Bouffet E, et al. Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children's Oncology Group. Neuro Oncol 2011;13:410-6.
3. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455:1061-8.
4. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008;321:1807-12.
5. Pollack IF, Hamilton RL, James CD, Finkelstein SD, Burnham J, Yates AJ, et al. Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: Results from the children's cancer group 945 cohort. J Neurosurg 2006;105:418-24. (Pubitemid 44954773)
6. Ganigi PM, Santosh V, Anandh B, Chandramouli BA, Sastry Kolluri VR. Expression of p53, EGFR, pRb and bcl-2 proteins in pediatric glioblastoma multiforme: A study of 54 patients. Pediatr Neurosurg 2005;41:292-9. (Pubitemid 41636332)
7. Pollack IF, Finkelstein SD, Burnham J, Hamilton RL, Yates AJ, Holmes EJ, et al. Age and TP53mutation frequency in childhood malignant gliomas: Results in a multi-institutional cohort. Cancer Res2005;61:7404-7. (Pubitemid 32995024)
8. Pollack IF, Finkelstein SD, Woods J, Burnham J, Holmes EJ, Hamilton RL, et al. Expression of p53 and prognosis in children with malignant gliomas. N Engl J Med 2003;346:420-7.
9. Sure U, Ruedi D, Tachibana O, Yonekawa Y, Ohgaki H, Kleihues P, et al. Determination of p53 mutations, EGFR overexpression, and loss of p16 expression in pediatric glioblastomas. J Neuropathol Exp Neurol 1997;56:782-9. (Pubitemid 27280188)
10. Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 2004;4:937-47. (Pubitemid 39626217)
11. McKay MM, Morrison DK. Integrating signals from RTKs to ERK/ MAPK. Oncogene 2007;26:3113-21. (Pubitemid 46763008)
12. Lopez-Gines C, Gil-Benso R, Benito R, Mata M, Pereda J, Sastre J, Roldan P, et al. The activation of ERK1/2 MAP kinases in glioblastoma pathobiology and its relationship with EGFR amplification. Neuropathol 2008;28:507-15.
13. Schiffman JD, Hodgson JG, VandenBerg SR, Flaherty P, Polley MY, Yu M, et al. Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Res 2010;70:512-9.
14. Paugh BS, Qu C, Jones C, Liu Z, Adamowicz-Brice M, Zhang J, et al. Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J Clin Oncol 2010; 28:3061-8.
15. Bax DA, Mackay A, Little SE, Carvalho D, Viana-Pereira M, Tamber N, et al. A distinct spectrum of copy number aberrations in pediatric high-grade gliomas. Clin Cancer Res 2010;16:3368-77.
16. McGillicuddy LT, Fromm JA, Hollstein PE, Kubek S, Beroukhim R, De Raedt T, et al. Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis. Cancer Cell 2009;16:44-54.
17. Knobbe CB, Reifenberger J, Reifenberger G. Mutation analysis of the ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas. Acta Neuropathol 2004;108:467-70. (Pubitemid 39534587)
18. Schindler G, Capper D, Meyer J, Janzarik W, Omran H, Herold-Mende C, et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 2011;121:397-405.
19. Morice C, Nothias F, Konig S, Vernier P, Baccarini M, Vincent JD, et al. RAF-1 and BRAF proteins have similar regional distributions but differential subcellular localization in adult rat brain. Eur J Neurosci 1999;11:1995-2006. (Pubitemid 29240565)
20. Wellbrock C, Karasarides M, Marais R. The RAF proteins take centre stage. Nat Rev Mol Cell Biol 2004;5:875-85. (Pubitemid 39486539)
21. Marais R, Light Y, Paterson HF, Mason CS, Marshall CJ. Differential regulation of raf-1, A-raf, and BRAF by oncogenic ras and tyrosine kinases. J Biol Chem 1997;272:4378-83. (Pubitemid 27078513)
22. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417: 949-54. (Pubitemid 34716871)
23. Tsavachidou D, Coleman ML, Athanasiadis G, Li S, Licht JD, Olson MF, et al. SPRY2 is an inhibitor of the ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant. Cancer Res 2004; 64:5556-9. (Pubitemid 39095548)
24. Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S, et al. Discovery of a selective inhibitor of oncogenic BRAF kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A 2008;105: 3041-6. (Pubitemid 351723664)
25. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809-19.
26. Torchia EC, Boyd K, Rehg JE, Qu C, Baker SJ. EWS/FLI-1 induces rapid onset of myeloid/erythroid leukemia in mice. Mol Cell Biol 2007;27:7918-34. (Pubitemid 350086425)
27. Kim JS, Lee C, Bonifant CL, Ressom H, Waldman T. Activation of p53- dependent growth suppression in human cells by mutations in PTEN or PIK3CA. Mol Cell Biol 2007;27:662-77. (Pubitemid 46080132)
28. Sarkaria JN, Yang L, Grogan PT, Kitange GJ, Carlson BL, Schroeder MA, et al. Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel. Mol Cancer Ther 2007;6: 1167-74. (Pubitemid 46554588)
29. Michaud K, Solomon DA, Oermann E, Kim JS, Zhong WZ, Prados MD, et al. Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. Cancer Res 2010;70:3228-38.
30. Hashizume R, Gupta N, Berger MS, Banerjee A, Prados MD, Ayers- Ringler J, et al. Morphologic and molecular characterization of ATRT xenografts adapted for orthotopic therapeutic testing. Neuro Oncol 2010;12:366-76.
31. Bhatt KV, Hu R, Spofford LS, Aplin AE. Mutant BRAF signaling and cyclin D1 regulate Cks1/S-phase kinase-associated protein 2-mediated degradation of p27Kip1 in human melanoma cells. Oncogene 2007;26:1056-66.
32. Schiappacassi M, Lovat F, Canzonieri V, Belletti B, Berton S, Di Stefano D, et al. p27Kip1 expression inhibits glioblastoma growth, invasion, and tumor-induced neoangiogenesis. Mol Cancer Ther 2008;7:1164-75.
33. Lavoie JN, L'Allemain G, Brunet A, Müller R, Pouysségur J. Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. J Biol Chem 1996; 271:20608-16. (Pubitemid 26281839)
34. Gysin S, Lee SH, Dean NM, McMahon M. Pharmacologic inhibition of RAF->MEK->ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1. Cancer Res 2005;65:4870-80. (Pubitemid 40740826)
35. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010;464:427-30.
36. Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010;464:431-5.
37. Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010;140: 209-21.
38. Zarghooni M, Bartels U, Lee E, Buczkowicz P, Morrison A, Huang A, et al. Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets. J Clin Oncol 2010;28:1337-44.
39. Pollack IF, Jakacki RI, Blaney SM, Hancock ML, Kieran MW, Phillips P, et al. Phase I trial of imatinib in children with newly diagnosed brain-stem and recurrent malignant gliomas: A pediatric brain tumor consortium report. Neuro Oncol 2007;9:145-60. (Pubitemid 46580316)
40. Prados MD, Chang SM, Butowski N, DeBoer R, Parvataneni R, Carliner H, et al. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol 2009;27:579-84.
41. Brown PD, Krishnan S, Sarkaria JN, Wu W, Jaeckle KA, Uhm JH, et al. Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North central cancer treatment group study N0177. J Clin Oncol 2008; 26:5603-9.
42. Stommel JM, Kimmelman AC, Ying H, Nabioullin R, Ponugoti AH, Wiedemeyer R, et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007; 318:287-90. (Pubitemid 47574858)
43. Mawrin C, Diete S, Treuheit T, Kropf S, Vorwerk CK, Boltze C, et al. Prognostic relevance of MAPK expression in glioblastoma multiforme. Int J Oncol 2003;23:641-8.
44. Jeuken J, van den Broecke C, Gijsen S, Boots-Sprenger S, Wesseling P. RAS/RAF pathway activation in gliomas: The result of copy number gains rather than activating mutations. Acta Neuropathol 2007; 114:121-33. (Pubitemid 47103523)
45. Long GV, Kefford RF, Carr PJA, et al. Phase 1/2 study of Gsk2118436, a selective inhibitor of V600 mutant (Mut) Braf Kinase: evidence of activity in melanoma brain metastases (Mets). European Society of Medical Oncolgy Congress 2010. Late Breaking Abstract. Ann Oncol 2010;21(Suppl 8): NP doi:10.1093/annonc/ mdq601. Abstract LBA27.
46. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507-16.